Dietary Supplement Use in Women Diagnosed with Breast Cancer.
botanical
breast cancer
chemotherapy
dietary supplement
endocrine therapy
hormone receptor
mineral
natural product
vitamin
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
21
10
2022
revised:
06
12
2022
accepted:
13
12
2022
pmc-release:
26
12
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
16
3
2023
Statut:
ppublish
Résumé
Vitamins, minerals, and natural product (NP)-derived dietary supplements are commonly used among women with breast cancer, where interactions with treatments and the disease are possible, emphasizing the importance for health care providers to be aware of supplement use. The study aimed to investigate current vitamin/mineral (VM) and NP supplement use among those diagnosed with breast cancer, including usage based on tumor type or concurrent breast cancer treatments and primary information sources for specific supplements. Social media recruiting to complete an online questionnaire self-reporting current VM and NP use and breast cancer diagnosis and treatment information primarily attracted US participants. Analyses, including multivariate logistic regression, were performed on 1271 women who self-reported breast cancer diagnosis and completed the survey. Most participants reported current VM (89.5%) and NP (67.7%) use, with 46.5% (VM) and 26.7% (NP) using at least 3 products concurrently. Top-reported (>15% prevalence) products were vitamin D, calcium, multivitamin, and vitamin C for VM and probiotics, turmeric, fish oil/omega-3 fatty acids, melatonin, and cannabis for NP. Overall, VM or NP use was higher among those with hormone receptor-positive tumors. Although overall NP use did not differ according to current breast cancer treatments, VM use was significantly less common among those currently undergoing chemotherapy or radiation, but higher with current endocrine therapy. Among current chemotherapy users, specific VM and NP supplements with possible adverse effects were still used by 23% of respondents. Medical providers were the primary information source for VM, whereas NP information sources were more varied. Because women diagnosed with breast cancer commonly reported concurrent use of multiple VM and NP supplements, including those with known or underexplored risks (or benefits) in breast cancer, it is important for health care providers to inquire about and facilitate discussions regarding supplement use in this population.
Sections du résumé
BACKGROUND
Vitamins, minerals, and natural product (NP)-derived dietary supplements are commonly used among women with breast cancer, where interactions with treatments and the disease are possible, emphasizing the importance for health care providers to be aware of supplement use.
OBJECTIVES
The study aimed to investigate current vitamin/mineral (VM) and NP supplement use among those diagnosed with breast cancer, including usage based on tumor type or concurrent breast cancer treatments and primary information sources for specific supplements.
METHODS
Social media recruiting to complete an online questionnaire self-reporting current VM and NP use and breast cancer diagnosis and treatment information primarily attracted US participants. Analyses, including multivariate logistic regression, were performed on 1271 women who self-reported breast cancer diagnosis and completed the survey.
RESULTS
Most participants reported current VM (89.5%) and NP (67.7%) use, with 46.5% (VM) and 26.7% (NP) using at least 3 products concurrently. Top-reported (>15% prevalence) products were vitamin D, calcium, multivitamin, and vitamin C for VM and probiotics, turmeric, fish oil/omega-3 fatty acids, melatonin, and cannabis for NP. Overall, VM or NP use was higher among those with hormone receptor-positive tumors. Although overall NP use did not differ according to current breast cancer treatments, VM use was significantly less common among those currently undergoing chemotherapy or radiation, but higher with current endocrine therapy. Among current chemotherapy users, specific VM and NP supplements with possible adverse effects were still used by 23% of respondents. Medical providers were the primary information source for VM, whereas NP information sources were more varied.
CONCLUSIONS
Because women diagnosed with breast cancer commonly reported concurrent use of multiple VM and NP supplements, including those with known or underexplored risks (or benefits) in breast cancer, it is important for health care providers to inquire about and facilitate discussions regarding supplement use in this population.
Identifiants
pubmed: 36913466
pii: S0022-3166(22)13251-7
doi: 10.1016/j.tjnut.2022.12.007
pmc: PMC10196584
pii:
doi:
Substances chimiques
Vitamins
0
Minerals
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-311Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 American Society for Nutrition. Published by Elsevier Inc. All rights reserved.
Références
J Nutr. 2020 Jun 1;150(6):1499-1508
pubmed: 32101612
NCHS Data Brief. 2021 Feb;(399):1-8
pubmed: 33663653
J Clin Oncol. 2018 Sep 1;36(25):2647-2655
pubmed: 29889605
J Altern Complement Med. 2018 Sep/Oct;24(9-10):902-909
pubmed: 30247957
Crit Rev Oncol Hematol. 2013 Dec;88(3):613-24
pubmed: 23932583
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13690
pubmed: 35977747
CA Cancer J Clin. 2017 May 6;67(3):194-232
pubmed: 28436999
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Clin Oncol. 2020 Mar 10;38(8):804-814
pubmed: 31855498
Breast Cancer Res Treat. 2022 Jan;191(2):385-388
pubmed: 34817746
Am J Surg. 2023 Jan;225(1):154-161
pubmed: 36030101
Cancer. 2022 Mar 15;128(6):1331-1338
pubmed: 34927236
Phytother Res. 2022 Apr;36(4):1761-1769
pubmed: 35181963
J Altern Complement Med. 2004 Aug;10(4):660-6
pubmed: 15353022
Br J Clin Pharmacol. 2021 Mar;87(3):741-753
pubmed: 32656820
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Breast Cancer Res Treat. 2016 Dec;160(3):539-546
pubmed: 27766453
Arthritis Care Res (Hoboken). 2019 Jun;71(6):787-797
pubmed: 29975014
J Cancer Res Clin Oncol. 2022 Jul 6;:
pubmed: 35790560
J Clin Oncol. 2008 Feb 1;26(4):665-73
pubmed: 18235127
J Med Internet Res. 2020 Jun 5;22(6):e17554
pubmed: 32501274
BMC Cancer. 2014 May 29;14:382
pubmed: 24884705
JMIR Public Health Surveill. 2016 Jul 11;2(2):e32
pubmed: 27400979
Integr Cancer Ther. 2017 Mar;16(1):85-95
pubmed: 27230757
Cochrane Database Syst Rev. 2022 Jan 10;1:CD013167
pubmed: 35005781
BMJ Case Rep. 2018 Sep 10;2018:
pubmed: 30206065
Nutrients. 2022 Aug 18;14(16):
pubmed: 36014907
Cancers (Basel). 2020 Aug 31;12(9):
pubmed: 32878124
J Nutr. 2020 Sep 1;150(9):2451-2459
pubmed: 32805045
J Bone Oncol. 2017 Mar 23;7:1-12
pubmed: 28413771
Plast Surg (Oakv). 2017 Nov;25(4):275-283
pubmed: 29619352
MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):43-47
pubmed: 35025856
Integr Cancer Ther. 2008 Sep;7(3):122-9
pubmed: 18956493
Cureus. 2021 Apr 29;13(4):e14754
pubmed: 34084680
BMC Complement Altern Med. 2011 Apr 15;11:30
pubmed: 21496245
Cancer. 2018 Mar 15;124(6):1207-1215
pubmed: 29211315
Cancer Nurs. 2010 May-Jun;33(3):194-200
pubmed: 20357652
Breast Cancer Res Treat. 2013 Feb;137(3):903-13
pubmed: 23306462